GSK’s COX-2 Plans: Complete Cardio Safety Study, Test Efficacy Of Low Doses
Executive Summary
GlaxoSmithKline is pushing back the anticipated NDA filing date for its Phase II COX-2 inhibitor to complete a cardiovascular safety study at the request of FDA, CEO J.P. Garnier said during an earnings call April 28
You may also be interested in...
Celebrex Shows “Overall Net Benefit” Versus NSAIDs, AHRQ Draft Report Says
The safety benefit of Pfizer's COX-2 inhibitor Celebrex compared to non-selective nonsteroidal anti-inflammatory drugs is affirmed in a draft report from the Agency for Healthcare Research & Quality on osteoarthritis treatments
Celebrex Shows “Overall Net Benefit” Versus NSAIDs, AHRQ Draft Report Says
The safety benefit of Pfizer's COX-2 inhibitor Celebrex compared to non-selective nonsteroidal anti-inflammatory drugs is affirmed in a draft report from the Agency for Healthcare Research & Quality on osteoarthritis treatments
Vioxx Route To Re-Approval Outlined By FDA As Merck Mulls Options
Conflicting opinions from FDA advisory committee members on the safety of Vioxx necessitates additional committee consideration prior to re-approval of the COX-2 inhibitor, an FDA memo states